New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|January 1, 2001
The American Journal of Managed Care
- January 2001
- Volume 7
- Issue 1
Can Administrative Database Studies Inform Medication Use Policy Decisions? An Application of Occam's Razor
Advertisement
Articles in this issue
over 25 years ago
Indirect Cost of Ischemic Heart Disease to Employersover 25 years ago
Disenrollment from Medicare HMOsover 25 years ago
A Comparison of Abciximab Use in MCO and Non-MCO Populationsover 25 years ago
The Employer's Perspectiveover 25 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?over 25 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?over 25 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?over 25 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5